A Phase III, Open-Label, Randomized Study To Investigate The Efficacy And Safety Of Atezolizumab (Anti?Pd L1 Antibody) Compared With Best Supportive C
Posted Date: May 15, 2019
- Investigator: Trisha Wise-Draper
- Type of Study: Drug
The purpose of this study is to look at the effects, good or bad, of atezolizumab on you and your NSCLC. Atezolizumab is an experimental drug, which means that health authorities have not approved atezolizumab for the treatment of NSCLC. Atezolizumab is an antibody that affects your immune system by
Criteria:
To Be Eligible, Patients Must Have Completely Resected Stage Ib-Iiia Non-Small Cell Lung Cancer
Keywords:
Go29527, Cancer, Resected Nsclc, Lung
For More Information:
Uc Cancer Center
5135847698
kastla@uc.edu